News – Page 860 – Endpoints News

SIGN UP

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs

7 years ago

House committee wants to know a lot more about the cyberattack that damaged Merck

7 years ago

Versartis shares hammered by a PhIII flop as growth hormone flunks key test

7 years ago

Sanofi, NIH create a three-pronged antibody to target HIV; Akari soars on PhIII plans; Juno plots planned $225M raise

7 years ago

A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up

7 years ago

Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus

7 years ago

With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII

7 years ago

Chris Garabedian's Xontogeny shepherds its first biotech through a $10M startup round

7 years ago

Want to start fixing the gender diversity problem in your biotech company? Put down the silver bullet

7 years ago

After settling with the SEC, biotech VC Steven Burrill now faces up to 30 years for fraud, tax evasion charges

7 years ago

FDA's Janet Woodcock: the clinical trials system is 'broken'

7 years ago

Arcus scores $305M regional development pact with Taiho; Shire, Shionogi tout PhIII ADHD study

7 years ago

Angry Pfizer accuses J&J of violating antitrust laws in safeguarding a megablockbuster franchise

7 years ago

Sanofi's Elias Zerhouni says his R&D group is ready to stand alone — but big M&A and partnerships still loom large

7 years ago

Lightstone crew adds a $250M Fund II with plans to back biotech startups

7 years ago

Tech maven Travis May takes the helm of Roivant's data mining startup

7 years ago

Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar

7 years ago

From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world

7 years ago

Troubled Teva turns to risk-sharing team at Nuvelution to gamble on a new PhIII study

7 years ago

OptiNose files for $100M IPO; GSK wins three-in-one COPD OK

7 years ago

OncoMed chief Paul Hastings goes on medical leave

7 years ago

Highlighting a major shift at the FDA, regulators put Amicus' once-spurned drug on fast track

7 years ago

With CRO consolidation in full swing, Catalent inks a $950M deal to acquire Cook Pharmica and signals an appetite for ...

7 years ago

Atlas ramps up a new biotech player focused on neurology, with a $30M round to fund the work

7 years ago

First page Previous page 857 858 859860861 862 863 Next page Last page